Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 13Endocrine 5Genitourinary 1

Conditions

Carcinoma, Renal Cell 84Kidney Neoplasms 22Prostatic Neoplasms 14Neoplasm Metastasis 10Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Hepatocellular 5Liver Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma 3Urethral Neoplasms 2Sarcoma 2Multiple Myeloma 2Hematologic Neoplasms 2Glioblastoma 2Financial Stress 2Wilms Tumor 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Germ Cell and Embryonal 1

Interventions

Magnetic Resonance Spectroscopy 4pembrolizumab 3Trastuzumab 3Sunitinib 3Nivolumab 3ulixertinib 2tipifarnib 2palbociclib 2lenvatinib 2belinostat 2Specimen Handling 2Sirolimus 2Radiosurgery 2Immunoglobulin G 2Fluorodeoxyglucose F18 2FAPI-46 2Disulfides 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1temsirolimus 1spartalizumab 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Sorafenib × Genitourinary × Clear all
NCT01502410 2018-06-26

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 14 charts
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Wilms Tumor, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡